The Effect of Recombinant Activated Factor VII on Mortality in Combat-Related Casualties With Severe Trauma and Massive Transfusion
ARMY INST OF SURGICAL RESEARCH FORT SAM HOUSTON TX
Pagination or Media Count:
Background The majority of patients with potentially survivable combat-related injuries die from hemorrhage. Our objective was to determine whether the use of recombinant activated factor VII rFVIIa decreased mortality in combat casualties with severe trauma who received massive transfusions and if its use was associated with increased severe thrombotic events. Methods We retrospectively reviewed a database of combat casualty patients with severe trauma Injury Severity Score ISS 15 and massive transfusion red blood cell RBCs 10 units24 hours admitted to one combat support hospital in Baghdad, Iraq, between December 2003 and October 2005. Admission vital signs and laboratory data, blood products, ISS, 24-hour and 30-day mortality, and severe thrombotic events were compared between patients who received rFVIIa rFVIIa and did not receive rFVIIa rFVIIa-. Conclusions The early use of rFVIIa was associated with decreased 30- mortality in severely injured combat casualties requiring massive transfusion, was not associated with increased risk severe thrombotic events.
- Medicine and Medical Research